Ligand Pharma (LGND) Tops Q4 EPS by 17c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $279.44 +6.59%
Revenue Growth %: +33.3%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +33.3%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.31, $0.17 better than the analyst estimate of $1.14. Revenue for the quarter came in at $50.5 million versus the consensus estimate of $47.82 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
- Nike names former Pfizer CFO David Denton as new finance chief
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
